Hair Growth-Promoting Effects of a Multi-Targeted Cosmetic Formulation Containing PYGL, DP2, and 15-PGDH Inhibitors Developed Using AI-Based DeepZema in Androgenetic Alopecia: A 24-Week Randomized Controlled Trial

The study evaluated the efficacy of a multi-targeted cosmetic formulation containing PYGL, DP2, and 15-PGDH inhibitors in promoting hair growth in individuals with androgenetic alopecia over 24 weeks. Conducted as a randomized controlled trial with 56 participants (49 completing the study), the formulation significantly improved hair density and thickness compared to the placebo group. The test group experienced a 4.43 n/cm² increase in hair density and a 0.010 mm increase in hair thickness, with no adverse effects reported. These findings suggest that the formulation could be a promising, safe, non-pharmacological treatment for androgenetic alopecia, although further research with larger populations is recommended.